Life Science REIT Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-40.04	-21.71	-27.61	18.58
Asset Writedown	41.3	22.85	31.31	-19.29
Change in Accounts Receivable	-1.71	-5.18	-8.14	-7.61
Change in Other Net Operating Assets	4.04	4.22	2.68	17.02
Other Operating Activities	8.18	7.43	0.67	-0.21
Operating Cash Flow	11.78	7.62	-1.09	8.49
Acquisition of Real Estate Assets	-30.28	-24.03	-187.06	-435.66
Sale of Real Estate Assets	7.36	9.17	-	-
Net Sale / Acq. of Real Estate Assets	-22.92	-14.87	-187.06	-435.66
Other Investing Activities	3.57	3.22	0.68	0.02
Investing Cash Flow	-19.35	-11.64	-186.38	-435.64
Long-Term Debt Issued	-	142.52	101.26	-
Long-Term Debt Repaid	-	-145.3	-26.26	-
Net Debt Issued (Repaid)	17.47	-2.78	75	-
Issuance of Common Stock	-	-	-	840
Common Dividends Paid	-7	-14	-3.5	-
Other Financing Activities	-11.73	-10.45	-4.39	-14.54
Net Cash Flow	-8.84	-31.27	-120.36	398.31
Cash Interest Paid	11.2	9.47	2.07	-
Levered Free Cash Flow	-32.75	-23.93	-7.19	-
Unlevered Free Cash Flow	-26.32	-17.93	-4.83	-
Change in Net Working Capital	2.3	-0.75	0.52	-

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.